Results 161 to 170 of about 11,456 (188)

Targeting NLRP3 Inflammasomes in Myocarditis: Potential Therapeutic Strategies and Clinical Translation. [PDF]

Scientifica (Cairo)
Retnowati FD, Halawa DR, Maayah ZH, Abdallah AM.   +3 more
europepmc   +1 more source

Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs. [PDF]

Curr Opin Physiol
Flanary SM, Yoshida K, Alejandro EU, Townsend D.   +3 more
europepmc   +1 more source

Metabolomic Analysis of the Effects of Canagliflozin on HFpEF Rats and Its Underlying Mechanism [PDF]

Endocr Metab Immune Disord Drug Targets
Zhang G, Zuo Q, Ma S, He L, Wang Z, Zhai J, Zhang T, Wang Y, Guo Y.   +8 more
europepmc   +1 more source

Trends in sodium-glucose transport protein 2 inhibitor prescriptions: application of the ATC/DDD system to NDB open data. [PDF]

Diabetol Int
Miyake T, Hashimoto M, Kadowaki D.
europepmc   +1 more source

Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. [PDF]

J Endocrinol Invest
Ajabnoor AM.
europepmc   +1 more source

The SGLT2 Inhibitor Canagliflozin Promotes β-Cell Regeneration and Restores and Stabilises β-Cell Identity in a Polygenic Model of Severe Early-Onset Type 2 Diabetes. [PDF]

J Cell Mol Med
Popescu I, Bunn RC, Ray P, Thrailkill KM, Fowlkes JL.   +4 more
europepmc   +1 more source

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) [PDF]

Circulation, 2018
Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and elevated ...
Bruce Neal, Vlado Perkovic
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity

Cell Metabolism, 2023
Ben Jenkins, Eric Ma, James Cronin
exaly